Want to see RIGL full AI Analyst Report?
RIGL Stock Chart & Stats
$46.75
-$0.08(-0.22%)
At close: 4:00 PM EDT
$46.75
-$0.08(-0.22%)
Day’s Range― - ―
52-Week Range$24.95 - $52.24
Previous CloseN/A
Volume485.30K
Average Volume (3M)290.29K
Market Cap
$909.15M
Enterprise Value$710.20
Total Cash (Recent Filing)$95.33M
Total Debt (Recent Filing)$39.95M
Price to Earnings (P/E)2.8
Beta1.79
Next Earnings
Nov 10, 2026EPS Estimate
0.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)17.67
Shares Outstanding18,679,865
10 Day Avg. Volume253,231
30 Day Avg. Volume290,294
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.97
Price to Sales (P/S)2.62
P/FCF Ratio10.18
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$65.00Price Target Upside39.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)3.46
Revenue Forecast (FY)$303.41M
Bulls Say, Bears Say
Bulls Say
Profitability And Cash GenerationRigel has shifted from earlier cash burn and losses to positive operating and free cash flow, while maintaining very high gross margins and positive operating profitability. This stronger internal funding base can support development and commercialization without relying as heavily on external capital.
Expanding Oncology PlatformThe VEPPANU license adds a differentiated oncology product with strong reported clinical efficacy and a sizable addressable market. Its addition broadens Rigel beyond existing hematology products and could materially increase commercial scale if launch execution converts clinical differentiation into adoption.
Conservative Current LeverageCurrent leverage is conservative relative to the company’s equity base, giving Rigel greater flexibility to fund product launches, clinical programs, and portfolio expansion. A stronger capital structure also reduces dependence on debt financing and improves resilience while the business executes its growth strategy.
Bears Say
Reduced Liquidity After VEPPANU InvestmentThe substantial decline in cash and short-term investments reduces liquidity headroom just as Rigel is funding a major product launch and ongoing development. Less available cash can constrain strategic flexibility and increase the importance of sustained product sales and disciplined expense management.
Recent Revenue Contraction And Weak ConversionThe latest TTM revenue decline interrupts stronger prior growth and raises questions about the durability of current earnings momentum. Because operating cash flow is below net income, reported profitability is not converting fully into cash, which could limit reinvestment capacity if the pattern persists.
VEPPANU Obligations May Pressure MarginsVEPPANU expands the opportunity set but carries substantial upfront, milestone, royalty, and development commitments. These obligations could absorb cash and reduce product-level margins over time, leaving Rigel more exposed to launch execution and the need to generate sufficient commercial returns.
Rigel News
RIGL FAQ
What was Rigel’s price range in the past 12 months?
Rigel lowest stock price was $24.95 and its highest was $52.24 in the past 12 months.
What is Rigel’s market cap?
Rigel’s market cap is $909.15M.
When is Rigel’s upcoming earnings report date?
Rigel’s upcoming earnings report date is Nov 10, 2026 which is in 63 days.
How were Rigel’s earnings last quarter?
Rigel released its earnings results on Aug 04, 2026. The company reported $0.88 earnings per share for the quarter, beating the consensus estimate of $0.088 by $0.792.
Is Rigel overvalued?
According to Wall Street analysts Rigel’s price is currently Undervalued.
Does Rigel pay dividends?
Rigel does not currently pay dividends.
What is Rigel’s EPS estimate?
Rigel’s EPS estimate is 0.92.
How many shares outstanding does Rigel have?
Rigel has 18,679,865 shares outstanding.
What happened to Rigel’s price movement after its last earnings report?
Rigel reported an EPS of $0.88 in its last earnings report, beating expectations of $0.088. Following the earnings report the stock price went up 4.599%.
Which hedge fund is a major shareholder of Rigel?
Currently, no hedge funds are holding shares in RIGL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rigel Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$65.00 (39.04% Upside)
$65.00 (39.04% Upside)
Blogger Sentiment
Bullish
RIGL Sentiment 83%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 1.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.28%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
152.04%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Rigel
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
RIGL Company Deck
RIGL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple meaningful commercial and pipeline achievements—most notably the in‑license and imminent launch of VEPPANU with strong phase III efficacy, ongoing commercial revenue growth (14% product sales growth, record TAVALISSE quarter, 27% REZLIDHIA growth), and promising early R289 data with regulatory incentives. These positives are tempered by lower year‑over‑year net income (partly due to one‑time prior‑year items), a substantial decline in cash reserves (~38.5%), higher operating expenses (+~35.7%), modest decline in GAVRETO sales, and significant upfront/milestone/royalty obligations tied to VEPPANU that may pressure margins and cash flow. Overall, the company communicated confident launch readiness and an optimistic strategic trajectory but with near‑term financial and execution risks to monitor.View all RIGL earnings summariesRIGL Stock 12 Month Forecast
Average Price Target
$65.00
▲(39.04% Upside)
Technical Analysis
Ownership Overview
3.30% Insiders
28.98% Mutual Funds
30.27% Other Institutional Investors
13.89% Public Companies and
Individual Investors